Gabriel Rendon, MD
Gastroenterology · McKinney, TXNPI 1235161761
Payments from drug & device makers
Across 702 payments — averaging $58.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Boston Scientific$1K
- Johnson & Johnson$799
- Medtronic$782
- Regeneron Healthcare Solutions, Inc.$710
- plus $6K from 34 others
What the payments were for
- Speaking & faculty fees$24,17559%
- Travel & lodging$9062%
- Food & beverage$15,65038%
- Education$610%
- Other$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 202 | $30,207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 116 | $1,532 |
| Boston Scientific | 48 | $1,224 |
| Johnson & Johnson | 40 | $799 |
| Medtronic(2 entities) | 9 | $782 |
| Regeneron Healthcare Solutions, Inc. | 21 | $710 |
| Pfizer | 36 | $605 |
| Daiichi Sankyo Inc. | 36 | $494 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $436 |
| Stryker | 2 | $354 |
| Sanofi | 11 | $334 |
| Lilly USA, LLC | 14 | $317 |
| Ardelyx, Inc. | 12 | $316 |
| Ferring Pharmaceuticals Inc. | 14 | $310 |
| Vivus LLC | 19 | $271 |
| Bristol Myers Squibb | 18 | $267 |
| Janssen Scientific Affairs, LLC | 2 | $232 |
| Abiomed | 5 | $211 |
| Merck | 9 | $200 |
| Redhill Biopharma Inc. | 4 | $132 |
| Nestle Healthcare Nutrition Inc. | 1 | $125 |
| Genentech USA, Inc. | 1 | $102 |
| Phathom Pharmaceuticals, Inc. | 5 | $100 |
| Madrigal Pharmaceuticals | 4 | $91 |
| UCB, Inc. | 5 | $86 |
| Ironwood Pharmaceuticals, Inc | 5 | $77 |
| Braintree Laboratories, Inc. | 4 | $64 |
| Amgen | 3 | $59 |
| Romark Laboratories, LC | 9 | $47 |
| Celltrion USA Inc. | 2 | $47 |
| Ambu Inc. | 2 | $43 |
| Abbott | 2 | $40 |
| Shionogi Inc | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Cook Medical LLC | 2 | $30 |
| Welch Allyn | 1 | $30 |
| QOL Medical, LLC | 1 | $26 |
| Intercept Pharmaceuticals, Inc. | 2 | $25 |
| Shire North American Group Inc | 1 | $21 |
| Gastrogpo, LLC | 4 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$16,958
- Skyrizi$602
- CoreValve Evolut$539
- Rinvoq$463
- CHROMOPHARE F300$354
- Tremfya$261
- DUPIXENT$243
- Entyvio$240
- STELARA$232
- REMICADE$232
- Resolution 360 Clip$145
- XELJANZ$126
- VOWST$125
- Humira$125
- INJECTAFER$125
- AXIOS$124
- IBSRELA$124
- ACQUIRE$115
- Impella$111
- EXALT Model D$111
How this compares
$40,822 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $327,399 |
| CreonLipase/Protease/Amylase | 28 | $142,965 |
| Humira PenAdalimumab | 14 | $98,407 |
| LinzessLinaclotide | 21 | $24,156 |
| Colesevelam Hcl | 34 | $5,426 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 36 | $4,396 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 26 | $4,297 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 23 | $3,197 |
| Sucralfate | 21 | $3,069 |
| Mesalamine | 21 | $2,819 |
| Pantoprazole Sodium | 107 | $1,169 |
| CholestyramineCholestyramine (With Sugar) | 16 | $1,060 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 14 | $929 |
| Esomeprazole Magnesium | 25 | $868 |
| Omeprazole | 58 | $807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $799 | $327,39912 claims |
| AbbVieCreon, Linzess | $30,207 | $167,12049 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $64 | $8,69362 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $436 | $3,19723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in McKinney
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
- Stephen HarrisonLive Oak$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.